Fox Christopher P, Boumendil Ariane, Schmitz Norbert, Finel Herve, Luan Jian J, Sucak Gülsan, Blaise Didier, Finke Jürgen, Pflüger Karl-Heinz, Veelken Hendrik, Gorin Norbert-Claude, Poiré Xavier, Ganser Arnold, Dreger Peter, Sureda Anna
a Clinical Haematology, Nottingham University Hospitals , Nottingham , UK.
b EBMT Lymphoma Working Party , Paris , France.
Leuk Lymphoma. 2015;56(12):3295-300. doi: 10.3109/10428194.2015.1037764. Epub 2015 Aug 26.
Extra-nodal NK/T lymphoma (ENKTL) is rare and more frequently encountered in East Asia. The role of high-dose therapy and autologous stem cell transplantation (HDT-ASCT) for ENKTL is unclear. Twenty-eight evaluable patients who had undergone HDT-ASCT in Europe from 2000-2009 were studied. The median age was 47 years and patients had received a median of two lines of prior therapy. Some 57% of patients were not in complete remission or beyond first complete remission at HDT-ASCT. The 1-year non-relapse mortality (NRM) was 11%; 2-year progression-free survival (PFS) and overall survival (OS) rates were 41% and 52%, respectively. Notably, the 2-year PFS and OS for those with stage III/IV disease were 33% and 40%, respectively, with no relapses beyond 1-year post-HDT-ASCT. This is the largest analysis of HDT-ASCT for patients with ENKTL reported from the Western hemisphere. Survival is comparable to East Asian cohorts and outcomes are encouraging for patients with advanced disease.
结外NK/T细胞淋巴瘤（ENKTL）较为罕见，在东亚地区更为常见。大剂量治疗及自体干细胞移植（HDT-ASCT）在ENKTL治疗中的作用尚不清楚。本研究纳入了2000年至2009年在欧洲接受HDT-ASCT治疗的28例可评估患者。患者的中位年龄为47岁，既往接受治疗的中位疗程数为2个疗程。约57%的患者在接受HDT-ASCT时未达到完全缓解或已超过首次完全缓解。1年无复发生存率（NRM）为11%；2年无进展生存率（PFS）和总生存率（OS）分别为41%和52%。值得注意的是，III/IV期疾病患者的2年PFS和OS分别为33%和40%，在HDT-ASCT后1年以上无复发。这是西半球报道的关于ENKTL患者HDT-ASCT的最大规模分析。生存率与东亚队列相当，晚期疾病患者的预后令人鼓舞。
